Skip to main content

Advertisement

SpringerLink
Log in

Usefulness of cell-free and concentrated ascites reinfusion therapy in the therapeutic management of advanced ovarian cancer patients with massive ascites

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

The management of refractory ascites in advanced ovarian cancer (AOC) is vital for patients with abdominal distention, respiratory distress, and anorexia due to massive ascites with cancer peritonitis. We analyzed the benefits of concentrated ascites reinfusion therapy (CART) in the management of AOC.

Methods

We reviewed records of AOC patients who underwent CART between January 2011 and March 2017. We retrospectively analyzed patients’ backgrounds and physiological changes, including body weight, abdominal girth, urine volume, blood component values, blood pressure, heart rate, and body temperature before and after CART. We investigated the clinicopathological significance of CART by measuring the mean number of ascites tumor cell (ATC) clusters before CART.

Results

A retrospective analysis was performed on 29 cases of AOC with massive ascites involving 47 CART sessions. The patients’ mean age was 56.6 ± 12.8 years, and the mean number of sessions was 1.7 ± 1.2. The mean volume of the processed ascites was 2,937 ± 820 mL, which was concentrated to 272 ± 84 mL containing 85.0 ± 33.2 g protein on average. Significant reductions in abdominal girth (− 5.30 ± 0.65 cm; p < 0.0001) and body weight (− 2.97 ± 0.26 kg; p = 0.0011), increased urine volume (+ 824.29 ± 145.21 mL; p < 0.0001), and improved serum albumin levels (+ 0.18 ± 0.34; p < 0.0001) were observed after CART. Analysis of variance revealed significant elevations in body temperature after CART in 11 patients with a small number of ATC clusters.

Conclusions

CART is useful for the therapeutic management of AOC patients with refractory massive ascites. Elevations of body temperature after CART may be avoided by the investigation of patients’ peritoneal cytology before CART.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kipps E, Tan DSP, Kaye SB (2013) Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer 13:273–282

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Chung M, Kozuch P (2008) Treatment of malignant ascites. Curr Treat Options Oncol 9:215–233

    Article  PubMed  Google Scholar 

  3. Becker G, Galandi D, Blum HE (2006) Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 42:589–597

    Article  PubMed  Google Scholar 

  4. Cavazzoni E, Bugiantella W, Graziosi L et al (2013) Malignant ascites: Pathophysiology and treatment. Int J Clin Oncol 18:1–9

    Article  PubMed  Google Scholar 

  5. Ahmed N, Stenvers KL (2013) Getting to know ovarian cancer ascites: Opportunities for targeted therapy-based translational research. Front Oncol 3:1–12

    Article  Google Scholar 

  6. Meier M, Mortensen FV, Madsen HHT (2015) Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter. Acta Radiol Open 4:2058460115579934

    PubMed Central  PubMed  Google Scholar 

  7. Gotlieb WH, Feldman B, Feldman-Moran O et al (1998) Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer. Gynecol Oncol 71:381–385

    Article  CAS  PubMed  Google Scholar 

  8. Lee CW, Bociek G, Faught W (1998) A survey of practice in management of malignant ascites. J Pain Symptom Manage 16:96–101

    Article  CAS  PubMed  Google Scholar 

  9. Boldt J (2010) Use of albumin: an update. Br J Anaesth 104:276–284

    Article  CAS  PubMed  Google Scholar 

  10. Ueda T, Maehara M, Takahashi Y et al (2012) Clinical significance of cell-free and concentrated ascites re-infusion therapy for advanced and recurrent gynecological cancer. Anticancer Res 32:2353–2358

    CAS  PubMed  Google Scholar 

  11. Inoue N, Yamazaki Z, Oda T et al (1977) Treatment of intractable ascites by continuous reinfusion of the sterilized cell-free and concentrated ascitic fluid. Trans Am Soc Artif Intern Organs 23:699–702

    Article  CAS  PubMed  Google Scholar 

  12. Kozaki K, IInuma M, Takagi T et al (2016) Cell-free and concentrated ascites reinfusion therapy for decompensated liver cirrhosis. Ther Apher Dial 20:376–382

    Article  CAS  PubMed  Google Scholar 

  13. Katoh S, Kojima T, Itoh K et al (1997) Usefulness of a nonmachinery based system for the reinfusion of cell-free and concentrated autogenous ascitic fluid. Artif Organs 21:1232–1238

    Article  CAS  PubMed  Google Scholar 

  14. Japanese CART Study Group, Matsusaki K, Ohta K, Yoshizawa A et al (2011) Novel cell-free and concentrated ascites reinfusion therapy (KM-CART) for refractory ascites associated with cancerous peritonitis: its effect and future perspectives. Int J Clin Oncol 16:395–400

    Article  Google Scholar 

  15. Yamaguchi H, Kitayama J, Emoto S et al (2015) Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1. Eur J Surg Oncol 41:875–880

    Article  CAS  PubMed  Google Scholar 

  16. Orimi S, Mizuno K, Narahara M et al (2011) A study of appropriate flow rate settings for cell-free and concentrated ascites reinfusion therapy and change of cytokine concentrations in ascites. Ther Apher Dial 15:411–414

    Article  CAS  PubMed  Google Scholar 

  17. Wang L, Okubo T, Shinsaka M et al (2015) Efficacy and safety of cell-free and concentrated ascites reinfusion therapy (CART) in gynecologic cancer patients with a large volume of ascites. J Obstet Gynaecol Res 41:1614–1620

    Article  CAS  PubMed  Google Scholar 

  18. Ito T, Hanafusa N, Fukui M et al (2014) Single center experience of cell-free and concentrated ascites reinfusion therapy in malignancy related ascites. Ther Apher Dial 18:87–92

    Article  PubMed  Google Scholar 

  19. Hanafusa N, Isoai A, Ishihara T et al (2017) Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: post-marketing surveillance results. PLoS One 12:1–21

    Article  CAS  Google Scholar 

  20. Cohen M, Petignat P (2014) The bright side of ascites in ovarian cancer. Cell Cycle 13:2319

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Maeda O, Ando T, Ishiguro K et al (2014) Safety of repeated cell–free and concentrated ascites reinfusion therapy for malignant ascites from gastrointestinal cancer. Mol Clin Oncol 2:1103–1106

    Article  PubMed Central  PubMed  Google Scholar 

  22. Maeda S, Yabuuchi J, Nobuta H et al (2015) Characteristics of patients and their ascites who underwent repeated cell-free and concentrated ascites reinfusion therapy. Ther Apher Dial 19:342–348

    Article  CAS  PubMed  Google Scholar 

  23. Layfield LJ, Mooney EE, Glasgow B et al (1997) What constitutes an adequate smear in fine-needle aspiration cytology of the breast? Cancer 81:16–21

    Article  CAS  PubMed  Google Scholar 

  24. Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655

    Article  CAS  PubMed  Google Scholar 

  25. Okuyama T, Wang XS, Akechi T et al (2003) Japanese version of the M.D. Anderson Symptom Inventory: a validation study. J Pain Symptom Manage 26:1093–1104

    Article  PubMed  Google Scholar 

  26. Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30

    Article  Google Scholar 

  27. Malvezzi M, Carioli G, Rodriguez T et al (2016) Global trends and predictions in ovarian cancer mortality. Ann Oncol 27:2017–2025

    Article  CAS  PubMed  Google Scholar 

  28. Agarwal R, Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3:502

    Article  CAS  PubMed  Google Scholar 

  29. Hansen JM, Coleman RL, Sood AK (2016) Targeting the tumour microenvironment in ovarian cancer. Eur J Cancer 56:131–143

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Sangisetty SL (2012) Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg 4:87

    Article  PubMed Central  PubMed  Google Scholar 

  31. Nakajima F, Shibahara N, Oka H et al (2001) Relationship between IL-6 levels and fever during ascites reinfusion therapy. Nihon Toseki Igakkai Zasshi 34:335–338

    Article  Google Scholar 

  32. Kalra A, Wedd JP, Bambha KM et al (2017) Neutrophil-to-lymphocyte ratio correlates with proinflammatory neutrophils and predicts death in low model for end-stage liver disease patients withcirrhosis. Liver Transpl 23:155–165

    Article  PubMed Central  PubMed  Google Scholar 

  33. Nagasaka K, Kawana K, Tomio K et al (2015) Positive peritoneal cytology at interval surgery is a poor prognostic factor in patients with stage T3c advanced ovarian carcinoma: a retrospective study. J Obstet Gynaecol Res 41:755–762

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors are grateful to Dr. Norio Hanafusa and Dr. Tetsuya Ito for valuable comments on the data preparation.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo, 113-8655, Japan

    Yoshiko Kawata, Kazunori Nagasaka, Yoko Matsumoto, Katsutoshi Oda, Michihiro Tanikawa, Kenbun Sone, Mayuyo Mori-Uchino, Tetsushi Tsuruga, Takahide Arimoto, Yutaka Osuga & Tomoyuki Fujii

  2. Department of Obstetrics and Gynecology, Teikyo University School of Medicine, Kaga 2-11-1, Itabashi-ku, Tokyo, 173-8655, Japan

    Kazunori Nagasaka

Authors
  1. Yoshiko Kawata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazunori Nagasaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoko Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Katsutoshi Oda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michihiro Tanikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kenbun Sone
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mayuyo Mori-Uchino
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tetsushi Tsuruga
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takahide Arimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yutaka Osuga
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tomoyuki Fujii
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kazunori Nagasaka.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kawata, Y., Nagasaka, K., Matsumoto, Y. et al. Usefulness of cell-free and concentrated ascites reinfusion therapy in the therapeutic management of advanced ovarian cancer patients with massive ascites. Int J Clin Oncol 24, 420–427 (2019). https://doi.org/10.1007/s10147-018-1371-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-018-1371-7

Keywords

Search

Navigation